RxDoctor Payments Data

Jennifer Phung, APRN

Family · New Haven, CTNPI 1316103542

Payments from drug & device makers

$3,729in general payments, 2019–2025

Across 192 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$750
  • Pfizer$418
  • E.r. Squibb & Sons, L.L.C.$389
  • AstraZeneca$339
  • Merck$293
  • Johnson & Johnson$281
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,68299%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,729 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$36,548
Medicare patients
227
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban916$801,087
XareltoRivaroxaban265$266,494
EntrestoSacubitril/Valsartan179$156,694
Repatha SureclickEvolocumab52$46,280
MultaqDronedarone Hcl22$22,966
JardianceEmpagliflozin32$22,665
OzempicSemaglutide11$17,155
VascepaIcosapent Ethyl42$15,617
BrilintaTicagrelor26$15,016
FarxigaDapagliflozin Propanediol18$13,672
EdarbiAzilsartan Medoxomil18$12,283
Potassium Chloride329$12,143
Praluent PenAlirocumab21$12,018
Ranolazine ErRanolazine137$10,833
Metoprolol Succinate769$8,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$801,087916 claims
Johnson & JohnsonXarelto$281$266,494265 claims
NovartisEntresto$175$156,694179 claims
AstraZenecaBrilinta, Farxiga, Atacand$339$32,07455 claims
Boehringer IngelheimJardiance, Pradaxa$255$25,86048 claims
Sanofi-aventis U.S. LLCMultaq$80$22,96622 claims
Novo NordiskOzempic$157$17,15511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →